Categories: News

Amarin to Present at Two Upcoming Investor Conferences

DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, will present at two upcoming investor conferences:

H.C. Wainwright Global Investment Conference (May 23-26, 2022; Miami, Florida)

Date/Time:       May 25, 2022, 12:00 p.m. ET/5:00 p.m. GMT+1
Webcast:          https://journey.ct.events/view/7aff40b1-3f90-47dd-a827-a30d854fea27

Jefferies Healthcare Conference (June 8-10, 2022; New York, New York)

Date/Time:       June 8, 2022, 1:00 p.m. ET/6:00 p.m. GMT+1
Webcast:          https://wsw.com/webcast/jeff240/amrn/1843950

Both conference presentations will be webcast live and archived on the Company’s website in the Investor Relations section under Events and Presentation at  Events | Amarin Corporation plc.

About Amarin  
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.  

Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information  
Investor Inquiries:  
Investor Relations  
Amarin Corporation plc  
IR@amarincorp.com (investor inquiries) 

Media Inquiries:
Communications  
Amarin Corporation plc  
PR@amarincorp.com (media inquiries)

 

Staff

Recent Posts

Avant Brands Announces $3.9 Million Private Placement of Unsecured Convertible Debenture Units

KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or…

2 hours ago

The International Myeloma Foundation Mourns the Passing of IMF Board Member and Support Group Leader Jack Aiello

STUDIO CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF)…

2 hours ago

Senti Bio Announces Reverse Stock Split

Shares expected to begin trading on split-adjusted basis on July 18, 2024SOUTH SAN FRANCISCO, Calif.,…

2 hours ago

CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial

Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI…

2 hours ago

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved…

2 hours ago